April 23, 2021 -- PerkinElmer is serving as a provider and co-developer of assays, instruments, and expertise for the ProxiDrugs Consortium, which is zeroing in on research for proximity drugs or proteolysis-targeting chimeras (PROTACs).
The research project, starting in October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (such as E3 ligases) so that they can be marked for destruction and recycled by the cells' natural shredding capabilities.
To help in these efforts, PerkinElmer will provide the consortium with immunoassay technologies, multimode plate readers, imaging technologies and platforms, and data analysis and informatics tools.
Copyright © 2021 scienceboard.net